COMMUNIQUÉS West-GlobeNewswire

Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib
30/06/2025
• In the Phase 1 portion of the CELC-G-201 clinical trial evaluating gedatolisib plus darolutamide in men with metastatic castration resistant prostate cancer (“mCRPC”), the six-month radiographic progression free [...]
Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act Litigation
30/06/2025
DUBLIN, June 30, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that, on Friday, June 27, 2025, the U.S. [...]
Tonix Pharmaceuticals Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
30/06/2025
CHATHAM, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biotechnology company, today announced that it will be added to the broad- [...]
Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting
30/06/2025
Data show that simufilam reduced seizure activity in a preclinical mouse model Presentation also highlights favorable human safety data from 1,929 patient Phase 3 program AUSTIN, Texas, June 30, 2025 (GLOBE NEWSWIRE [...]
U.S. Department of Health and Human Services Designates Four Nutrients of Public Health Concern Validating Glucose Health, Inc. (OTC: GLUC) Patent Pending Soluble Fiber-Based Nutrition Formulation
30/06/2025
BENTONVILLE, Ark., June 30, 2025 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC: GLUC), a publicly traded company specializing in diabetic nutrition and soluble fiber-based nutrition products, today commented on the U.S [...]
Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions
30/06/2025
Phase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southern Hemisphere Briefing documents submitted to FDA for a Type D meeting request to continue [...]
PathAI Receives FDA Clearance for AISight® Dx Platform for Primary Diagnosis
30/06/2025
BOSTON, June 30, 2025 (GLOBE NEWSWIRE) -- PathAI, a global leader in artificial intelligence (AI) and digital pathology solutions, today announced that it has received 510(k) clearance from the U.S. Food and Drug [...]
HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy
30/06/2025
— Approval based on Phase III SACHI Trial results which showed a 66% reduced risk of progression or death as compared to platinum-based chemotherapy — — The only all-oral combination treatment option for these patients [...]
Affidea Group selects b-rayZ as its preferred AI partner in breast imaging, marking strategic collaboration
30/06/2025
THE HAGUE, The Netherlands, June 30, 2025 (GLOBE NEWSWIRE) -- In a strategic move to improve patient outcomes in breast cancer, Affidea , a leading pan-European provider of community-based polyclinics, specialist [...]
Le groupe Affidea choisit b-rayZ comme partenaire d’IA privilégié en imagerie mammaire, marquant ainsi le début d’une collaboration stratégique
30/06/2025
LA HAYE, Pays-Bas, 30 juin 2025 (GLOBE NEWSWIRE) -- Dans une démarche stratégique visant à améliorer les résultats des patientes atteintes d’un cancer du sein, Affidea , l’un des principaux prestataires paneuropéens de [...]
Rakovina Therapeutics Highlights Strong H1 Progress and Unveils Strategic Priorities for H2 2025
30/06/2025
VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies [...]
AB Science provides an update on the renegotiation of loan repayment terms with its financial creditors
30/06/2025
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE RENEGOTIATION OF LOAN REPAYMENT TERMS WITH ITS FINANCIAL CREDITORS AGREEMENT IN PRINCIPLE HAS BEEN REACHED ON A TWO-YEAR DEFERRAL OF REPAYMENT OF STATE-GUARANTEED LOANS [...]
AB Science fait un point sur la renégociation des modalités de remboursement de ses emprunts avec ses créanciers financiers
30/06/2025
COMMUNIQUE DE PRESSE AB SCIENCE FAIT UN POINT SUR LA RENEGOCIATION DES MODALITES DE REMBOURSEMENT DE SES EMPRUNTS AVEC SES CREANCIERS FINANCIERS UN ACCORD DE PRINCIPE A ETE OBTENU SUR UN DECALAGE DE DEUX ANS DU [...]
SAFE - Informations complémentaires concernant le report de publication des résultats annuels 2024 - Suspension de la cotation de l’action Safe par Euronext à compter du 1er juillet 2025
30/06/2025
Informations complémentaires concernant le report de publication des résultats annuels 2024 Suspension de la cotation de l’action Safe par Euronext à compter du 1 er juillet 2025 Fleurieux-sur-l’Arbresle – France – 30 [...]
Press release: Availability of the Q2 2025 Aide mémoire
30/06/2025
Availability of the Q2 2025 Aide mémoire Paris, France – June 30, 2025 . Sanofi announced today that its Q2 2025 Aide mémoire is available on the "Investors" page of the company's website: Second quarter 2025 (sanofi. [...]
Communiqué de presse : Mise en ligne du document «Q2 2025 Aide mémoire »
30/06/2025
Mise en ligne du document «Q2 2025 Aide mémoire » Paris, France, le 30 juin 2025 . Sanofi annonce la mise en ligne sur l'espace Investisseurs du site internet de la société, d'un document intitulé « Q2 2025 Aide mémoire [...]
Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial
30/06/2025
Press Release Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial Results expected mid-August to mid-September 2025 New Drug Application (NDA) submission in the U.S. targeted for H1 2026 [...]
Nicox annonce que le dernier patient a terminé l’essai clinique de Phase 3 Denali sur NCX 470
30/06/2025
Communiqué de presse Nicox annonce que le dernier patient a terminé l’essai clinique de Phase 3 Denali sur NCX 470 Les premiers résultats sont attendus entre mi-août et mi-septembre 2025 L’autorisation de mise sur le [...]
Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy
30/06/2025
Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a potential first-in-class [...]

Pages